179 related articles for article (PubMed ID: 35420472)
1. Isolation of a Potently Neutralizing and Protective Human Monoclonal Antibody Targeting Yellow Fever Virus.
Doyle MP; Genualdi JR; Bailey AL; Kose N; Gainza C; Rodriguez J; Reeder KM; Nelson CA; Jethva PN; Sutton RE; Bombardi RG; Gross ML; Julander JG; Fremont DH; Diamond MS; Crowe JE
mBio; 2022 Jun; 13(3):e0051222. PubMed ID: 35420472
[TBL] [Abstract][Full Text] [Related]
2. A Chimeric Japanese Encephalitis Vaccine Protects against Lethal Yellow Fever Virus Infection without Inducing Neutralizing Antibodies.
Mishra N; Boudewijns R; Schmid MA; Marques RE; Sharma S; Neyts J; Dallmeier K
mBio; 2020 Apr; 11(2):. PubMed ID: 32265332
[TBL] [Abstract][Full Text] [Related]
3. A humanized monoclonal antibody neutralizes yellow fever virus strain 17D-204 in vitro but does not protect a mouse model from disease.
Calvert AE; Dixon KL; Piper J; Bennett SL; Thibodeaux BA; Barrett AD; Roehrig JT; Blair CD
Antiviral Res; 2016 Jul; 131():92-9. PubMed ID: 27126613
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic neutralizing monoclonal antibody administration protects against lethal yellow fever virus infection.
Ricciardi MJ; Rust LN; Pedreño-Lopez N; Yusova S; Biswas S; Webb GM; Gonzalez-Nieto L; Voigt TB; Louw JJ; Laurino FD; DiBello JR; Raué HP; Barber-Axthelm AM; Chun K; Uttke S; Raphael LMS; Yrizarry-Medina A; Rosen BC; Agnor R; Gao L; Labriola C; Axthelm M; Smedley J; Julander JG; Bonaldo MC; Walker LM; Messaoudi I; Slifka MK; Burton DR; Kallas EG; Sacha JB; Watkins DI; Burwitz BJ
Sci Transl Med; 2023 Mar; 15(689):eade5795. PubMed ID: 36989376
[TBL] [Abstract][Full Text] [Related]
5. Type III Interferon-Mediated Signaling Is Critical for Controlling Live Attenuated Yellow Fever Virus Infection
Douam F; Soto Albrecht YE; Hrebikova G; Sadimin E; Davidson C; Kotenko SV; Ploss A
mBio; 2017 Aug; 8(4):. PubMed ID: 28811340
[TBL] [Abstract][Full Text] [Related]
6. A chimeric yellow fever-Zika virus vaccine candidate fully protects against yellow fever virus infection in mice.
Kum DB; Boudewijns R; Ma J; Mishra N; Schols D; Neyts J; Dallmeier K
Emerg Microbes Infect; 2020; 9(1):520-533. PubMed ID: 32116148
[TBL] [Abstract][Full Text] [Related]
7. Development of a Bicistronic Yellow Fever Live Attenuated Vaccine with Reduced Neurovirulence and Viscerotropism.
Wang HJ; Guo Y; He MJ; Liu ZY; Ye Q; Huang XY; Deng YQ; Li XF; Qin CF
Microbiol Spectr; 2022 Oct; 10(5):e0224622. PubMed ID: 35980184
[TBL] [Abstract][Full Text] [Related]
8. Genotype-specific features reduce the susceptibility of South American yellow fever virus strains to vaccine-induced antibodies.
Haslwanter D; Lasso G; Wec AZ; Furtado ND; Raphael LMS; Tse AL; Sun Y; Stransky S; Pedreño-Lopez N; Correia CA; Bornholdt ZA; Sakharkar M; Avelino-Silva VI; Moyer CL; Watkins DI; Kallas EG; Sidoli S; Walker LM; Bonaldo MC; Chandran K
Cell Host Microbe; 2022 Feb; 30(2):248-259.e6. PubMed ID: 34998466
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of safety and immuno-efficacy of a next generation live-attenuated yellow fever vaccine in cynomolgus macaques.
Piras-Douce F; Broudic K; Chautard E; Raynal F; Courtois V; Gautheron S; Mantel N
Vaccine; 2023 Feb; 41(8):1457-1470. PubMed ID: 36702693
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model.
Julander JG; Testori M; Cheminay C; Volkmann A
Front Immunol; 2018; 9():1756. PubMed ID: 30116244
[TBL] [Abstract][Full Text] [Related]
11. Molecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone.
Jiang X; Dalebout TJ; Lukashevich IS; Bredenbeek PJ; Franco D
J Gen Virol; 2015 Apr; 96(Pt 4):804-814. PubMed ID: 25516543
[TBL] [Abstract][Full Text] [Related]
12. Clinical evidence for the immunogenicity and immune persistence of vaccination with yellow fever virus strain 17D in Chinese peacekeepers deployed to Africa.
Jia Q; Jia C; Liu Y; Yang Y; Qi J; Tong L; Chen H; Zhang M; Che J; Li B; Li Z
Antiviral Res; 2019 Feb; 162():1-4. PubMed ID: 30529359
[TBL] [Abstract][Full Text] [Related]
13. A mouse model for studying viscerotropic disease caused by yellow fever virus infection.
Meier KC; Gardner CL; Khoretonenko MV; Klimstra WB; Ryman KD
PLoS Pathog; 2009 Oct; 5(10):e1000614. PubMed ID: 19816561
[TBL] [Abstract][Full Text] [Related]
14. A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse model.
Thibodeaux BA; Garbino NC; Liss NM; Piper J; Schlesinger JJ; Blair CD; Roehrig JT
Antiviral Res; 2012 Apr; 94(1):1-8. PubMed ID: 22366350
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of humoral immune response after yellow fever infection: an observational study on patients from the 2017-2018 sylvatic outbreak in Brazil.
Gonçalves AP; Almeida LT; Rezende IMd; Fradico JRB; Pereira LS; Ramalho DB; Pascoal Xavier MA; Calzavara Silva CE; Monath TP; LaBeaud AD; Drumond BP; Campi-Azevedo AC; Martins-Filho OA; Teixeira-Carvalho A; Alves PA;
Microbiol Spectr; 2024 May; 12(5):e0370323. PubMed ID: 38511952
[TBL] [Abstract][Full Text] [Related]
16. Live-attenuated YF17D-vectored COVID-19 vaccine protects from lethal yellow fever virus infection in mouse and hamster models.
Ma J; Yakass MB; Jansen S; Malengier-Devlies B; Van Looveren D; Sanchez-Felipe L; Vercruysse T; Weynand B; Javarappa MPA; Quaye O; Matthys P; Roskams T; Neyts J; Thibaut HJ; Dallmeier K
EBioMedicine; 2022 Sep; 83():104240. PubMed ID: 36041265
[TBL] [Abstract][Full Text] [Related]
17. Activation and Kinetics of Circulating T Follicular Helper Cells, Specific Plasmablast Response, and Development of Neutralizing Antibodies following Yellow Fever Virus Vaccination.
Sandberg JT; Ols S; Löfling M; Varnaitė R; Lindgren G; Nilsson O; Rombo L; Kalén M; Loré K; Blom K; Ljunggren HG
J Immunol; 2021 Aug; 207(4):1033-1043. PubMed ID: 34321231
[TBL] [Abstract][Full Text] [Related]
18. Humanized monoclonal antibody 2C9-cIgG has enhanced efficacy for yellow fever prophylaxis and therapy in an immunocompetent animal model.
Julander JG; Thibodeaux BA; Morrey JD; Roehrig JT; Blair CD
Antiviral Res; 2014 Mar; 103():32-8. PubMed ID: 24393669
[TBL] [Abstract][Full Text] [Related]
19. T Cell Responses Induced by Attenuated Flavivirus Vaccination Are Specific and Show Limited Cross-Reactivity with Other Flavivirus Species.
Grifoni A; Voic H; Dhanda SK; Kidd CK; Brien JD; Buus S; Stryhn A; Durbin AP; Whitehead S; Diehl SA; De Silva AD; Balmaseda A; Harris E; Weiskopf D; Sette A
J Virol; 2020 May; 94(10):. PubMed ID: 32132233
[TBL] [Abstract][Full Text] [Related]
20. The 17D-204 Vaccine Strain-Induced Protection against Virulent Yellow Fever Virus Is Mediated by Humoral Immunity and CD4+ but not CD8+ T Cells.
Watson AM; Lam LK; Klimstra WB; Ryman KD
PLoS Pathog; 2016 Jul; 12(7):e1005786. PubMed ID: 27463517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
